Comparison of nocturia response to desmopressin treatment in elderly men with and without nocturnal polyuria in real-life practice

• Published in: International journal of clinical practice (Esher) Vol. 70; no. 5; pp. 372 - 379
• Main Authors: Chen, S.-L., Huang, Y.-H., Hung, T.-W., Ou, Y.-C.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.05.2016; Hindawi Limited
• Subjects: Aged; Aged, 80 and over; Antidiuretic Agents - therapeutic use; Deamino Arginine Vasopressin - therapeutic use; Drug therapy; Geriatrics; Humans; Male; Medical disorders; Middle Aged; Nocturia - drug therapy; Nocturia - etiology; Polyuria - drug therapy; Polyuria - etiology; Prostatic Hyperplasia - complications; Retrospective Studies; Urology
• ISSN: 1368-5031; 1742-1241
• DOI: 10.1111/ijcp.12786

Summary Objectives To evaluate the safety and efficacy of low‐dose desmopressin in elderly men with and without nocturnal polyuria (NP) in real‐life practice. Methods Patients with lower urinary tract symptoms (LUTS)/ benign prostate hyperplasia (BPH) who were≧ 65 years old with refractory nocturia were enrolled in this study. We retrospectively analysed elderly men treated with adding desmopressin to current medications for nocturia according to category of the baseline nocturnal urine volume. The 48‐h frequency volume chart (FVC), International Prostate Symptom Score (IPSS) and quality of life (QoL) were initially assessed and re‐evaluated 12 weeks later. Serum sodium level was checked 1 week, 4 weeks, and 12 weeks after initiation of desmopressin therapy or suspected hyponatremia event. The mean change in numbers of nocturnal voids was evaluated for efficacy of treatment. Results A total of 136 patients were included with 55 in non‐NP group and 81 in NP group. Hypertension was more common in NP group in regard of comorbidities. During treatment period, there were significant reductions of nocturnal voids from 4.22 ± 1.38 to 2.31 ± 0.98 (p < 0.001) in non‐NP group and from 4.52 ± 1.23 to 2.07 ± 0.89 (p < 0.001) in NP group. The reduction in nocturnal voids was more significant in NP group (2.44 ± 1.15 vs. 1.91 ± 1.48, p = 0.003). The mean decrease in serum sodium levels were 3.89 ± 1.22 mmol/l (p < 0.001) in non‐NP group and 4.69 ± 3.5 mmol/l (p < 0.001) in NP group at the extreme value. Conclusions Long‐term treatment with low‐dose desmopressin is safe and effective for nocturia with or without NP in elderly patients with LUTS/BPH during real‐life practice. Patients should be well informed about the disease and are closely followed.